Literature DB >> 31419462

Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model.

Mahdiyeh Bahramizadeh1, Maryam Bahramizadeh1, Bita Kiafar2, Amir Hossein Jafarian3, Amin Reza Nikpoor4, Mahdi Hatamipour5, Habibollah Esmaily6, Zari Rezaeemehr7, Shiva Golmohammadzadeh5, Seyedeh Alia Moosavian5, Mahmoud Reza Jafari8.   

Abstract

The aim of this study was to prepare and characterize topical methotrexate (MTX) with different percentages (0.05%, 0.1%, 0.25% and 0.5%) entrapped in deformable liposomes using phosphatidylcholine and oleic acid. The effectiveness and sub-acute toxicity of these topical formulations were investigated in imiquimod (IMQ)-induced psoriasis in a mouse model (IMQP). The particle sizes of formulations were around 100 nm with a mean zeta potential of -72.87 mV. The entrapment efficiency (EE%) of MTX in liposomal formulations were more than 85%. Franz cell permeability studies indicated that permeation of MTX through the healthy BALB/c mice skin is very low; however, in the inflammatory skin, which was induced by IMQ it was significant (50%). Liposomal MTX (LM 0.05 and 0.1%) caused significant reduction of thickness score dose-dependently in IMQP compared to the injected MTX. Moreover, investigation of the inflammatory factor and pathological examinations of skin proved the superiority of the LM treating group. Pathological examinations also showed there are no toxicity in organs of the mice that received the LM. Blood cell count test didn't show any abnormality. MTX-entrapped deformable liposomes could be a topical option in future for the treatment of human psoriasis with a less toxicity and merit further investigations.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal model; Deformable topical liposomes; Methotrexate; Oleic acid; Psoriasis

Mesh:

Substances:

Year:  2019        PMID: 31419462     DOI: 10.1016/j.ijpharm.2019.118623

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects.

Authors:  Ummu Umaimah Mohd Nordin; Noraini Ahmad; Norazlinaliza Salim; Nor Saadah Mohd Yusof
Journal:  RSC Adv       Date:  2021-09-01       Impact factor: 4.036

Review 2.  Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis.

Authors:  Prativa Biswasroy; Deepak Pradhan; Biswakanth Kar; Goutam Ghosh; Goutam Rath
Journal:  AAPS PharmSciTech       Date:  2021-05-26       Impact factor: 3.246

3.  TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients.

Authors:  Vanessa Lucília Silveira de Medeiros; Fabiana Cristina Fulco Santos; Lílian Maria Lapa Montenegro; Maria da Conceição Silva; Valdênia Maria Oliveira de Souza; Reginaldo Gonçalvez de Lima Neto; Líbia Cristina Rocha Vilela Moura; Vera Magalhães
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

4.  Topical Unsaturated Fatty Acid Vesicles Improve Antioxidant Activity of Ammonium Glycyrrhizinate.

Authors:  Maria Chiara Cristiano; Antonia Mancuso; Massimo Fresta; Daniele Torella; Federica De Gaetano; Cinzia Anna Ventura; Donatella Paolino
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

Review 5.  Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.

Authors:  Andrea Cassinotti; Alberto Batticciotto; Marco Parravicini; Maurizio Lombardo; Paolo Radice; Claudio Camillo Cortelezzi; Simone Segato; Federico Zanzi; Antonella Cappelli; Sergio Segato
Journal:  Therap Adv Gastroenterol       Date:  2022-03-23       Impact factor: 4.409

Review 6.  Experimental research in topical psoriasis therapy (Review).

Authors:  Diana Ana-Maria Nițescu; Alina Mușetescu; Maria Nițescu; Monica Costescu; Oana-Andreia Coman
Journal:  Exp Ther Med       Date:  2021-07-08       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.